

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Jenscare Scientific Co., Ltd.
寧波健世科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 9877)

VOLUNTARY ANNOUNCEMENT
THE APPROVAL OF KEN-VALVE BY THE HONG KONG
DEPARTMENT OF HEALTH HAS BEEN GRANTED

This announcement is made by Jenscare Scientific Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to provide the shareholders and potential investors of the Company with updated information in relation to the latest business and product development of the Group.

The board of directors (the “**Directors**”) of the Company (the “**Board**”) is pleased to announce that the Company’s Ken-Valve Transcatheter Aortic Valve Replacement System has recently obtained approval from the Department of Health of the Hong Kong Special Administrative Region of the People’s Republic of China (the “**Hong Kong Department of Health**”). The Company is actively advancing the commercialisation of this product in Hong Kong.

Supported by its differentiated competitive strengths, sustained therapy promotion and extensive commercial application experience, Ken-Valve has gained widespread market recognition. The approval of Ken-Valve by the Hong Kong Department of Health further validates the product’s potential in the treatment of aortic regurgitation (or combined aortic stenosis). The Company will continue to comprehensively accelerate the global commercialisation of Ken-Valve to further achieve the Company’s long-term strategic objectives.

Cautionary Statement as required by Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: There is no assurance that the Company will ultimately market and/or commercialise Ken-Valve successfully. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
Jenscare Scientific Co., Ltd.
Mr. PAN Fei
Executive Director and Chief Executive Officer

Hong Kong, 22 June 2026

As at the date of this announcement, the executive Director is Mr. PAN Fei; the non-executive Directors are Mr. LV Shiwen, Mr. TAN Ching, Mr. ZHENG Jiaqi, Ms. XIE Youpei and Mr. CHEN Xinxing; and the independent non-executive Directors are Dr. LIN Shoukang, Ms. DU Jiliu and Dr. MEI Lehe.